Navigation Links
Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device for Use with NovoLog®
Date:3/1/2011

BRIDGEWATER, N.J., March 1, 2011 /PRNewswire/ -- Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that the U.S. Food and Drug Administration has cleared the company's V-Go Disposable Insulin Delivery Device for use with Novo Nordisk's NovoLog® for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin.  In December 2010, Valeritas received FDA clearance for the V-Go's use with Eli Lilly's Humalog®.

"With the addition of NovoLog® to the V-Go label, we have demonstrated that the two most widely prescribed fast acting insulins in the United States can be used safely with the V-Go and thereby have increased healthcare professional and patient insulin options available for use with the V-Go Disposable Insulin Delivery Device," said Valeritas CEO Kristine Peterson.  

About the V-Go Disposable Insulin Delivery Device

The V-Go is the first simple, fully disposable device for the delivery of basal-bolus insulin therapy for adults with diabetes. The V-Go provides a continuous preset basal rate of insulin and allows for on-demand bolus dosing around mealtimes thereby providing an alternative to taking multiple daily insulin injections.  

The V-Go is engineered to simplify basal-bolus insulin therapy for the millions of people suffering from Type 2 diabetes. The V-Go is small, lightweight, and worn under the patients' clothing. It measures just 2.4 x 1.3 x 0.5 inches and weighs approximately 1 ounce when filled with insulin. Patients apply a new V-Go to the skin daily for one 24-hour period. The V-Go is not electronic, making it easy to operate and use.

The V-Go is filled with insulin using a very simple point-of-care filling accessory – the EZ Fill (which will be included with each monthly supply of V-Go devices).  A separate prescription for insulin is required for use with the V-Go.  Humalog® and NovoLog® have both been tested by Valeritas, Inc. and found safe for use with the V-Go Disposable Insulin Delivery Device.

About Valeritas, Inc.

Valeritas is a medical technology company committed to the development and commercialization of innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes.  The Valeritas medical technologies portfolio is headlined by the h-Patch™ technology.  The V-Go Disposable Insulin Delivery Device, designed for the simple delivery of basal-bolus insulin therapy via a preset basal rate and on-demand bolus dosing around mealtimes, is the first use of the h-Patch™ technology.

In addition to the V-Go, the Valeritas delivery technology portfolio includes the

h-Patch™ for the delivery of other compounds in addition to insulin, the Mini-Ject™ Pre-Filled Needle-Free Delivery System, and the Micro-Trans™ Microneedle Delivery System.  These technologies, when combined with certain compounds, are designed to enhance the delivery of a variety of injectable drugs resulting in improved patient acceptance and outcomes.

Headquartered in Bridgewater, NJ, Valeritas operates its R&D and manufacturing in a state-of-the-art facility in Shrewsbury, MA. Valeritas' primary investors include MPM Capital, Pitango Venture Capital, Abingworth, US Venture Partners, ONSET Ventures, ATV Capital, HLM Venture Partners, CHL Medical Partners, Kaiser Permanente Ventures, and Agate Medical Investments.

Information on Valeritas and the V-Go™ Disposable Insulin Delivery Device can be found at www.valeritas.com and www.go-vgo.com.

NovoLog is a registered trademark of Novo Nordisk A/S.

Humalog is a registered trademark of Eli Lilly and Company.


'/>"/>
SOURCE Valeritas, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device
2. Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
3. Mylan Receives Approval for Generic Version of Neurontin® Capsules
4. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
5. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
6. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
7. Delcath Systems Receives Refusal to File Letter From FDA
8. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
9. Sevocity, a Division of Conceptual MindWorks, Incs Sevocity Receives ONC-ATCB 2011/2012 Certification
10. Jardogs FollowMyHealth™ Universal Health Record Receives ONC-ATCB Certification
11. AirPal Receives Patent for Inflatable Patient Positioning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... 2035" report to their offering. ... The Deep Learning: Drug Discovery and Diagnostics Market, ... growing market of deep learning solutions within the healthcare domain. Primarily ... as a novel solution to generate relevant insights from medical data. ...
(Date:3/24/2017)... , March 24, 2017 ... the industry including definitions, classifications, applications and industry chain ... international market including development history, competitive landscape analysis, and ... ... industry spread across 105 pages providing 10 company profiles ...
(Date:3/24/2017)... 2017 Research and Markets has announced the ... Report" report to their offering. ... The report provides separate comprehensive analytics for the US, ... , Asia-Pacific , Latin America ... the period 2015 through 2022. Also, a six-year historic analysis is provided ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The iaedp Foundation, the premier ... professionals caring for those suffering from the full spectrum of disordered eating, announced today ... disorders professionals from nearly all 50 states and several countries converged on the Green ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... wanted to create a communications platform that positions them as the go-to thought ... ONS reinvented their online publication as an always-on, always-fresh news, views and advocacy ...
(Date:3/24/2017)... ... March 24, 2017 , ... Viewers who like to educate themselves on current ... practices, goods, services, and societal issues tend to appreciate and love the "Informed" series, ... of utilizing running events for causes around the world. , Running for ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Finding Christ ... #TruthwithGrace”: a devotional journal chronicling the writer’s path toward true communion with God. ... with God #TruthwithGrace” is the creation of published author Lea Michelle Johnson, a ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
Breaking Medicine News(10 mins):